{"id":643828,"date":"2023-03-22T17:56:01","date_gmt":"2023-03-22T17:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=643828"},"modified":"2023-03-22T17:56:01","modified_gmt":"2023-03-22T17:56:01","slug":"adrenoleukodystrophy-ald-market-to-observe-stupendous-growth-during-the-forecast-period-20222032-delveinsight-bluebird-bio-minoryx-ashvattha-viking-therapeutics-magenta-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/adrenoleukodystrophy-ald-market-to-observe-stupendous-growth-during-the-forecast-period-20222032-delveinsight-bluebird-bio-minoryx-ashvattha-viking-therapeutics-magenta-therapeutics_643828.html","title":{"rendered":"Adrenoleukodystrophy (ALD) Market to Observe Stupendous Growth During the Forecast Period (2022-2032) – DelveInsight | bluebird bio, Minoryx, Ashvattha, Viking Therapeutics, Magenta Therapeutics"},"content":{"rendered":"
\n
\"Adrenoleukodystrophy<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Adrenoleukodystrophy (ALD) Market is anticipated to evolve immensely in the coming years owing to the awareness about newborn screening programs as well as an increase in the number of ALD cases and the launch of new therapies in the market.<\/div>\n

The key players in the Adrenoleukodystrophy therapeutics market include Bluebird Bio, Minoryx Therapeutics and Magenta Therapeutics,<\/strong> and others. Of the emerging therapies, the most anticipated products to get approved in upcoming years are Lenti-D (Gene therapy; Bluebird Bio), Leriglitazone (MIN-102) (Minoryx Therapeutics), and MGTA-456 (Magenta Therapeutics).<\/strong><\/em><\/p>\n

DelveInsight’s “Adrenoleukodystrophy (ALD) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adrenoleukodystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Adrenoleukodystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Adrenoleukodystrophy (ALD): An Overview<\/strong><\/p>\n

Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, which leads to the development of seizures and hyperactivity.<\/p>\n

The disease mainly affects males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may also be clinically affected. There are three basic forms of ALD: neonatal, childhood, and adult-onset. Childhood ALD is the classical and the most severe form, leading to total disability or death. It affects only boys because the genetic defect is sex-linked (carried on the X-chromosome).<\/p>\n

Adrenoleukodystrophy (ALD) Market Key Facts<\/strong><\/p>\n